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Efﬁcacy and Safety of Apixaban Compared With Warfarin in Patients
With Atrial Fibrillation and Peripheral Artery Disease: Insights From
the ARISTOTLE Trial
Peter T. Hu, MD; Renato D. Lopes, MD, PhD, MHS; Susanna R. Stevens, MS; Lars Wallentin, MD, PhD; Laine Thomas, PhD; John H. Alexander,
MD, MHS; Michael Hanna, MD; Basil S. Lewis, MD; Freek W. A. Verheugt, MD, PhD; Christopher B. Granger, MD; W. Schuyler Jones, MD
Background-—We studied (1) the rates of stroke or systemic embolism and bleeding in patients with atrial ﬁbrillation and peripheral
artery disease (PAD) and (2) the efﬁcacy and safety of apixaban versus warfarin in patients with atrial ﬁbrillation with and without PAD.
Methods and Results-—The Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE)
trial randomized 18 201 patients with atrial ﬁbrillation to apixaban or warfarin for stroke/systemic embolism prevention; 884
(4.9%) patients had PAD at baseline. Patients with PAD had higher unadjusted rates of stroke and systemic embolism (hazard ratio
[HR] 1.73, 95% CI 1.22–2.45; P=0.002) and major bleeding (HR 1.34, 95% CI 1.00–1.81; P=0.05), but after adjustment, no
differences existed in rates of stroke and systemic embolism (HR 1.32, 95% CI 0.93–1.88; P=0.12) and major bleeding (HR 1.03,
95% CI 0.76–1.40; P=0.83) compared with patients without PAD. The risk of stroke or systemic embolism was similar in patients
assigned to apixaban and warfarin with PAD (HR 0.63, 95% CI 0.32–1.25) and without PAD (HR 0.80, 95% CI 0.66–0.96; interaction
P=0.52). Patients with PAD did not have a statistically signiﬁcant reduction in major or clinically relevant nonmajor bleeding with
apixaban compared with warfarin (HR 1.05, 95% CI 0.69–1.58), whereas those without PAD had a statistically signiﬁcant reduction
(HR 0.65, 95% CI 0.58–0.73; interaction P=0.03).
Conclusions-—Patientswith PAD in ARISTOTLE had a higher crude risk of stroke or systemic embolism comparedwith patientswithout
PAD that was not present after adjustment. The beneﬁts of apixaban versus warfarin for stroke and systemic embolism were similar in
patients with and without PAD. These ﬁndings highlight the need to optimize the treatment of patients with atrial ﬁbrillation and PAD.
Clinical Trial Registration-—URL: http://www.clinicaltrials.gov. Unique identiﬁer: NCT00412984. ( J Am Heart Assoc. 2017;6:
e004699. DOI: 10.1161/JAHA.116.004699.)
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T he rates of both peripheral artery disease (PAD) andatrial ﬁbrillation (AF) are increasing, with an estimated
33.5 million people with AF and 202 million with PAD
worldwide.1,2 Patients with PAD and AF are at increased risk
of stroke. Stroke risk scores have been developed for patients
with AF and, with the exception of the recently created ABC
risk score, are based on clinical variables.3 The CHA2DS2-
VASc risk score for stroke and systemic embolism incorpo-
rates vascular disease, which includes myocardial infarction
(MI), aortic plaque, and PAD. The inclusion of vascular disease
in the CHA2DS2-VASc risk score emphasizes the importance
of PAD as a risk factor in patients with AF.4,5 Nevertheless,
there are limitations to incorporating PAD into the CHA2DS2-
VASc scoring system, including a small number (N=62 [5.7%])
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of patients with PAD in the validation cohort and the exclusion
of patients with PAD on oral anticoagulation at baseline.4,5
Recent data from a large PAD cohort on oral anticoagulation
at baseline found no statistically signiﬁcant difference in risk
of stroke or systemic embolism in patients with PAD but did
ﬁnd a treatment effect on bleeding risk with type of oral
anticoagulant therapy.6 The use of non–vitamin K antagonist
oral anticoagulants in the treatment of AF is increasing;
however, little is known about the effectiveness and safety of
these newer agents in patients with PAD.7–9
In the Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
comparing apixaban and warfarin in patients with AF,
apixaban was superior to warfarin in preventing stroke and
systemic embolism and reducing major bleeding.10 In this
analysis of ARISTOTLE, we aimed to evaluate (1) the
association of PAD with clinical outcomes (stroke, systemic
embolism, and bleeding) and (2) the effectiveness and safety
of apixaban and warfarin in patients with AF with and without
PAD.
Methods
ARISTOTLE was a randomized, double-blind, double-dummy
trial comparing apixaban with dose-adjusted warfarin in
18 201 patients with AF and at least 1 risk factor for stroke.
The study design was described previously.11 Patients were
randomly assigned to twice-daily dosing of apixaban 5 mg or
dose-adjusted warfarin (target International Normalized Ratio
2.0–3.0). Key exclusion criteria were AF due to a reversible
cause, moderate or severe mitral stenosis, conditions other
than AF requiring anticoagulation, stroke within the previous
7 days, need for aspirin at a dose of >165 mg per day or both
aspirin and clopidogrel, and severe renal insufﬁciency. The
trial was designed and approved by a steering committee and
approved by appropriate ethics committees at all sites. All
patients provided written informed consent.
Deﬁnition of PAD
The presence of PAD was designated by site investigators and
reported on the case report form. Those with a history of PAD
were included in the PAD cohort. The presence of carotid
artery stenosis and aortic aneurysm was captured separately
and did not constitute PAD.
Outcomes
The primary efﬁcacy outcome was ischemic or hemorrhagic
stroke or systemic embolism. Secondary efﬁcacy outcomes
included death from any cause and rate of MI. The primary
safety outcome was major bleeding, as deﬁned by the
International Society on Thrombosis and Haemostasis (ISTH).
Secondary safety outcomes included a composite of major
bleeding and clinically relevant nonmajor bleeding. A clinical
events committee, whose members were not aware of study
group assignments, adjudicated the primary and secondary
efﬁcacy and safety outcomes.
Statistical Analysis
The current analysis is a subgroup analysis of the ARISTOTLE
population; however, it was not prespeciﬁed prior to the
completion of the study. Cox proportional hazards regression
models were used to assess (1) the association between PAD
and efﬁcacy and safety outcomes and (2) the treatment effect
of apixaban versus warfarin within subgroups of patients with
and without PAD.
All models were stratiﬁed by prior vitamin K antagonist use
and region. Adjustment variables for each end point were
determined by model selection in the full ARISTOTLE cohort.
Adjustment variables for stroke or systemic embolism
included age; weight; diabetes mellitus; hypertension; moder-
ate valvular disease; prior stroke, transient ischemic attack, or
systemic embolism; and type of AF. For the end points of all-
cause and cardiovascular death, adjustment variables
included age; sex; systolic blood pressure; diastolic blood
pressure; weight; hypertension; moderate valvular disease;
left bundle-branch block; prior MI; prior stroke, transient
ischemic attack, or systemic embolism; anemia; smoking;
New York Heart Association classiﬁcation; CHADS2 score; and
renal function. Adjustment variables for MI included age,
diabetes mellitus, coronary artery disease, prior MI, New York
Heart Association classiﬁcation, and renal function. Adjust-
ment variables for all bleeding end points included age, sex,
coronary artery disease, history of MI, prior bleeding, anemia,
CHADS2 score, and renal function.
Outcomes are presented as events per 100 patient-years
of follow-up. Risk relationships are presented as adjusted
hazard ratios (HRs) with 95% CIs derived from the adjusted
Cox models. Categorical variables were compared for those
with and without PAD using chi-square tests and are
presented as count per number not missing (percentage).
Continuous variables were compared by Wilcoxon rank sum
tests and are presented as medians (25th, 75th percentiles).
Results
Study Population
A total of 18 201 patients were enrolled in the ARISTOTLE
trial. PAD status was reported in 17 980 patients. Of those,
884 (4.9%) had PAD at baseline and were included in this
analysis. Baseline demographics and patient characteristics
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according to the presence or absence of PAD are shown in
Table 1.
Participants with PAD were more likely to be older, male,
and current smokers. They were more likely to have a
history of diabetes mellitus, MI, coronary artery disease,
carotid artery disease, or moderate or worse valvular heart
disease and to have been on warfarin previously and had a
higher risk of bleeding and fall within the previous year.
Patients with PAD were more likely to be on aspirin,
clopidogrel, or any aspirin or thienopyridine at baseline, at
1 year of follow-up, and at the time of study drug
discontinuation (Table 2).
Table 1. Baseline Demographics and Patient Characteristics by History of PAD
Variable PAD (n=884) No PAD (n=17 096) P Value
Age, y, median (25th, 75th) 73 (66.5, 79) 70 (62, 76) <0.0001
Female sex 251/884 (28.4) 6090/17 096 (35.6) <0.0001
Region <0.0001
North America 307/884 (34.7) 4133/17 096 (24.2)
Latin America 138/884 (15.6) 3299/17 096 (19.3)
Europe 368/884 (41.6) 6893/17 096 (40.3)
Asia Pacific 71/884 (8.0) 2771/17 096 (16.2)
CHADS2 score, meanSD 2.661.25 2.091.09 <0.0001
≤1 164/884 (18.6) 5929/17 096 (34.7)
2 284/884 (32.1) 6152/17 096 (36.0)
≥3 436/884 (49.3) 5015/17 096 (29.3)
Presenting characteristics
Systolic BP, mm Hg, median (25th, 75th) 130 (120, 140) 130 (120, 140) 0.2785
Weight, kg, median (25th, 75th) 83.0 (71.5, 95.8) 82.0 (70.0, 95.5) 0.1417
Moderate or severe renal impairment 228/884 (25.8) 2745/17 021 (16.1) <0.0001
Baseline comorbidities
History of stroke, TIA, or systemic embolism 295/884 (33.4) 3189/17 096 (18.7) <0.0001
Carotid disease (bruit, stent, stenosis, endarterectomy) 169/884 (19.1) 441/17 096 (2.6) <0.0001
Nonparoxysmal AF type 745/884 (84.3) 14 470/17 093 (84.7) 0.7609
Prior warfarin/VKA 553/884 (62.6) 9721/17 096 (56.9) 0.0008
Coronary artery disease 523/884 (59.2) 5469/17 092 (32.0) <0.0001
Myocardial infarction 257/884 (29.1) 2297/17 094 (13.4) <0.0001
CHF within 3 months or LVEF ≤40% 363/884 (41.1) 6000/17 096 (35.1) 0.0003
Diabetes mellitus 325/884 (36.8) 4172/17 096 (24.4) <0.0001
Hypertension 813/884 (92.0) 14 991/17 096 (87.7) 0.0001
Current smoking 89/884 (10.1) 1378/17 079 (8.1) 0.0343
Moderate or worse valvular heart disease 239/884 (27.0) 2953/17 094 (17.3) <0.0001
History of bleeding 213/884 (24.1) 2794/17 093 (16.3) <0.0001
History of fall within previous year 77/828 (9.3) 669/15 451 (4.3) <0.0001
Medications
ACEI or ARB 668/877 (76.2) 12 053/16 817 (71.7) 0.0039
Beta blocker 603/877 (68.8) 10 767/16 817 (64.0) 0.0044
Aspirin 345/884 (39.0) 5231/17 096 (30.6) <0.0001
Clopidogrel 33/884 (3.7) 300/17 096 (1.8) <0.0001
ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial ﬁbrillation; ARB, angiotensin receptor blocker; BP, blood pressure; CHF, congestive heart failure; LVEF, left ventricular
ejection fraction; PAD, peripheral artery disease; TIA, transient ischemic attack; VKA, vitamin K antagonist.
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Outcomes in Patients With and Without PAD
Rates of efﬁcacy end points and corresponding HRs for
patients with PAD compared with patients without PAD are
shown in Table 3. The overall unadjusted rate of stroke or
systemic embolism was higher in patients with versus
without PAD (HR 1.73, 95% CI 1.22–2.45; P=0.002), but
after adjustment for differences in patient characteristics, no
difference was present in rates of stroke or systemic
embolism (HR 1.32, 95% CI 0.93–1.88; P=0.12). Those with
PAD had an increased risk of all-cause death (HR 1.36, 95%
CI 1.11–1.67; P=0.003) and cardiovascular death (HR 1.44,
95% CI 1.08–1.90; P=0.01) compared with those without
PAD.
Rates of bleeding end points and corresponding HRs for
patients with PAD compared with those without PAD are also
shown in Table 3. Crude rates of ISTH major bleeding were
higher in patients with versus without PAD (HR 1.34, 95% CI
1.00–1.81; P=0.05), but no difference in event rates was
present after adjustment (HR 1.03, 95% CI 0.76–1.40;
P=0.83) between patients with and without PAD. Clinically
overt bleeding was more common in patients with PAD
compared with those without PAD (HR 1.61, 95% CI 1.13–
2.30; P=0.008), and patients with PAD were more likely to
have mucosal bleeding (HR 1.58, 95% CI 1.07–2.33; P=0.02)
and gastrointestinal bleeding (HR 1.72, 95% CI 1.11–2.67;
P=0.02) compared with those without PAD. There was no
statistically signiﬁcant difference in intracranial bleeding (HR
1.19, 95% CI 0.60–2.35; P=0.63) in patients with PAD
compared with those without PAD.
Apixaban Versus Warfarin in Patients With and
Without PAD
The effect of apixaban versus warfarin for the prevention of
stroke or systemic embolism was similar in patients with PAD
(HR 0.63, 95% CI 0.32–1.25) and without PAD (HR 0.80, 95%
CI 0.66–0.96; interaction P=0.52) (Figures 1 and 2). The
effect of apixaban versus warfarin on all-cause death was also
similar in patients with PAD (HR 1.03, 95% CI 0.71–1.51) and
without PAD (HR 0.88, 95% CI 0.78–0.99; interaction P=0.42).
Patients with PAD appeared to have no difference in ISTH
major bleeding with apixaban compared with warfarin (HR 0.81,
95% CI 0.46–1.44) versus those without PAD (HR 0.68, 95% CI
0.59–0.79; interaction P=0.58) (Figure 1). Patients with PAD
had no statistically signiﬁcant reduction in major or clinically
relevant nonmajor bleeding (HR 1.05, 95% CI 0.69–1.58) with
apixaban compared with warfarin, whereas those without PAD
had a statistically signiﬁcant reduction in major or clinically
relevant nonmajor bleeding (HR 0.65, 95% CI 0.58–0.73;
interaction P=0.03) with apixaban compared with warfarin.
Similar results were seen for the outcome of clinically relevant
nonmajor bleeding alone (apixaban versus warfarin: HR 1.39,
95% CI 0.77–2.50; patients with versus without PAD: HR 0.65,
95% CI 0.56–0.75; interaction P=0.01) (Figure 3, Table S1).
Table 2. Antiplatelet Use at Baseline and During Follow-up
PAD (All) No PAD (All) PAD (Apixaban) PAD (Warfarin) No PAD (Apixaban) No PAD (Warfarin)
Baseline
Patients, n 884 17 096 442 442 8564 8532
ASA 345 (39.0) 5231 (30.6) 160 (36.2) 185 (41.9) 2668 (31.2) 2563 (30.0)
Clopidogrel 33 (3.7) 300 (1.8) 21 (4.8) 12 (2.7) 146 (1.7) 154 (1.8)
Any ASA or thienopyridine 376 (42.5) 5477 (32.0) 179 (40.5) 197 (44.6) 2786 (32.5) 2691 (31.5)
At 1 year
Patients, n 793 15 976 398 395 8037 7939
ASA 222 (28.0) 3311 (20.7) 95 (23.9) 127 (32.2) 1713 (21.3) 1598 (20.1)
Clopidogrel 34 (4.3) 238 (1.5) 18 (4.5) 16 (4.1) 124 (1.5) 114 (1.4)
Any ASA or thienopyridine 247 (31.1) 3484 (21.8) 110 (27.6) 137 (34.7) 1800 (22.4) 1684 (21.2)
At time of study drug discontinuation*
Patients, n 884 17 096 442 442 8564 8532
ASA 263 (29.8) 3559 (20.8) 115 (26.0) 148 (33.5) 1828 (21.3) 1731 (20.3)
Clopidogrel 31 (3.5) 244 (1.4) 18 (4.1) 13 (2.9) 113 (1.3) 131 (1.5)
Any ASA or thienopyridine 289 (32.7) 3742 (21.9) 130 (29.4) 159 (36.0) 1914 (22.3) 1828 (21.4)
ASA indicates aspirin; PAD, peripheral artery disease.
*Or at the time of last contact.
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Discussion
As new therapies are introduced and utilized in the treatment
of AF, it is imperative to understand the impact of
comorbidities such as PAD on clinical outcomes. This analysis
of patients with PAD in ARISTOTLE had 4 major ﬁndings. First,
crude rates of stroke and bleeding were higher among those
with PAD, but after adjustment for differences in patient
characteristics, there was no difference in rate of stroke or
systemic embolism and bleeding in patients with versus
without PAD. Second, patients with PAD had an increased risk
of all-cause death and cardiovascular death compared with
those without PAD. Third, the effect of apixaban versus
warfarin for the prevention of stroke or systemic embolism
was consistent in patients with and without PAD. Fourth, the
reduction in bleeding with apixaban in the whole trial cohort
was not observed in this relatively small subgroup with PAD.
Our ﬁrst major ﬁnding, that the presence of PAD was not
statistically signiﬁcantly associated with stroke or systemic
embolism, was not entirely surprising. A simple explanation
for this is the low number of stroke or systemic embolic
events in patients with PAD (N=32) thus limiting the power to
detect a difference. The current results are similar to a post
hoc analysis of patients with PAD in ROCKET AF (Rivaroxaban
Once daily, oral, direct factor Xa inhibition Compared with
vitamin K antagonism for prevention of stroke and Embolism
Trial in Atrial Fibrillation). In ROCKET AF, patients with PAD
compared with those without PAD did not have a statistically
signiﬁcant increase in stroke or systemic embolism (HR 1.04,
95% CI 0.72, 1.50; P=0.84).6 Our results are congruent with
this prior analysis and suggest that in patients with AF and at
least 1 additional risk factor for stroke who are on oral
anticoagulant therapy, the presence of PAD is not indepen-
dently associated with a substantial increase in risk of stroke.
For patients not on anticoagulation, whether the presence of
PAD (including as a sole factor) is associated with risk of
stroke cannot be addressed with our study.
Our second ﬁnding, that PAD was associated with a higher
risk of all-cause death and cardiovascular death in patients
with PAD compared with those without PAD, is consistent
with prior studies and has been seen across many different
cardiovascular trials and registries.12 PAD alone has been
shown to be a powerful independent predictor of coronary
and cerebrovascular disease. In addition, worsening PAD
severity has been associated with increased mortality in
Table 3. Association Between PAD and Outcomes
Outcomes
PAD Events
(Rate)
No PAD
Events (Rate)
Unadjusted
HR (95% CI)
Unadjusted
P Value
Adjusted HR
(95% CI)
Adjusted
P Value
Efficacy end points
Stroke or systemic embolism 34 (2.17) 440 (1.40) 1.73 (1.22–2.45) 0.0022 1.32 (0.93–1.88) 0.1227
All-cause death 108 (6.71) 1151 (3.58) 1.97 (1.61–2.40) <0.0001 1.36 (1.11–1.67) 0.0033
Cardiovascular death 58 (3.60) 586 (1.82) 2.13 (1.62–2.79) <0.0001 1.44 (1.08–1.90) 0.0117
MI 19 (1.20) 171 (0.54) 2.02 (1.26–3.26) 0.0037 1.25 (0.77–2.03) 0.3722
Safety end points
ISTH major bleeding 47 (3.42) 731 (2.56) 1.34 (1.00–1.81) 0.0504 1.03 (0.76–1.40) 0.8256
ISTH major or clinically relevant nonmajor bleeding 92 (6.85) 1380 (4.93) 1.38 (1.12–1.71) 0.0027 1.12 (0.90–1.39) 0.3114
Clinically relevant nonmajor bleeding 45 (3.30) 710 (2.50) 1.29 (0.96–1.75) 0.0957 1.10 (0.81–1.50) 0.5416
GUSTO moderate or severe bleed 36 (2.61) 486 (1.69) 1.57 (1.12–2.21) 0.0089 1.22 (0.86–1.72) 0.2709
TIMI major or minor bleed 41 (2.98) 560 (1.95) 1.56 (1.13–2.14) 0.0063 1.22 (0.88–1.70) 0.2226
ISTH major bleeding type
Required transfusion 27 (1.96) 294 (1.02) 1.80 (1.21–2.68) 0.0036 1.32 (0.88–1.98) 0.1840
Required a medical or surgical intervention
to stop bleeding
12 (0.86) 218 (0.76) 1.15 (0.64–2.06) 0.6383 0.97 (0.54–1.76) 0.9242
Required changes in antithrombotic therapy 33 (2.39) 360 (1.25) 1.86 (1.30–2.66) 0.0007 1.41 (0.98–2.04) 0.0665
Required hospitalization 29 (2.10) 338 (1.17) 1.76 (1.21–2.58) 0.0035 1.28 (0.86–1.89) 0.2178
Fatal bleeding 2 (0.14) 17 (0.06) 2.87 (0.65–12.62) 0.1624 1.94 (0.42–8.94) 0.3960
ISTH major bleeding site
Intracranial 9 (0.65) 165 (0.57) 1.35 (0.69–2.64) 0.3869 1.19 (0.60–2.35) 0.6250
GUSTO indicates Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries; HR, hazard ratio; ISTH, International Society on Thrombosis and Haemostasis;
MI, myocardial infarction; PAD, peripheral artery disease; TIMI, Thrombolysis in Myocardial Infarction.
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patients with multiple disease states.13,14 We were unable to
validate this ﬁnding in the present analysis because of limited
information regarding severity of PAD in the ARISTOTLE
data set.
Our third major ﬁnding is that the beneﬁt of apixaban
versus warfarin for the prevention of stroke or systemic
embolism was similar in patients with and without PAD. These
results are consistent with the main trial results from
Figure 1. Treatment effects according to PAD. GUSTO indicates Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded Arteries; ISTH, International Society on Thrombosis and
Haemostasis; MI, myocardial infarction; PAD indicates peripheral artery disease; TIMI, thrombolysis in
myocardial infarction.
Figure 2. Kaplan–Meier plot for cumulative rate of stroke or
systemic embolism in patients classiﬁed by PAD and treatment
assignment. PAD indicates peripheral artery disease.
Figure 3. Kaplan–Meier plot for major or clinically relevant
nonmajor bleeding classiﬁed by PAD status and treatment
assignment. PAD indicates peripheral artery disease.
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ARISTOTLE, which found that apixaban was superior to
warfarin in preventing stroke or systemic embolism in the
entire study population.10 This helps provide conﬁdence that
apixaban can be used effectively to prevent stroke or
systemic embolism in patients with AF with and without PAD.
In terms of bleeding risk, patients with PAD did not have a
signiﬁcantly increased risk of major bleeding compared with
patients without PAD. In those who had overt bleeding,
patients with PAD were more likely than those without PAD to
have mucosal or gastrointestinal bleeding, but the overall
event rates were low in both groups. This can be explained, at
least in part, by the greater use of antiplatelet agents among
patients with PAD (Table 2). Patients with PAD, compared
with those without PAD, were more likely to be on aspirin,
clopidogrel, or any aspirin or thienopyridine at baseline, at 1-
year follow-up, and at the time of study drug discontinuation.
In addition to antiplatelet therapy, the impact of PAD itself
(related to something inherent about the disease, the need for
invasive procedures, or other factors) may also contribute to
an increased bleeding risk.
Interestingly, our study found a treatment interaction
with apixaban compared with warfarin in patients with PAD.
Patients with PAD had no statistically signiﬁcant reduction
in major or clinically relevant nonmajor bleeding with
apixaban compared with warfarin, whereas those without
PAD had a statistically signiﬁcant reduction in major or
clinically relevant nonmajor bleeding. Prior analysis of the
ARISTOTLE trial found a similar interaction in patients with
diabetes mellitus, which is of interest because PAD and
diabetes mellitus are often comorbid conditions.15 Our
current results are consistent with a similarly sized post
hoc analysis of patients with AF with PAD enrolled in
ROCKET AF, in which patients with PAD had a higher risk
of major bleeding or clinically relevant nonmajor bleeding
with rivaroxaban compared with warfarin.6 Although the use
of antiplatelet agents at baseline and during the study may
have contributed to this effect, patients with PAD on
warfarin were more likely to be on concomitant antiplatelet
therapy compared with patients with PAD on apixaban.
These ﬁndings may not fully represent and explain the
impact of antiplatelet agents on bleeding with warfarin and
apixaban because patients may have been started on
aspirin and/or a thienopyridine after year 1 and before
study drug discontinuation. Furthermore, a prior analysis of
the ARISTOTLE trial regarding concomitant aspirin use
found that apixaban actually caused signiﬁcantly less
bleeding among both aspirin and nonaspirin users com-
pared with warfarin.16 This makes it less likely that
concomitant aspirin use alone is driving this interaction.
Finally, one should always consider the play of chance
when analyzing results from small subgroups like patients
with AF and PAD in the ARISTOTLE trial.
Limitations
This analysis has several limitations. First, given its post hoc
nature, our results should be interpreted as hypothesis
generating rather than deﬁnitive. The multivariable model
attempts to account for known confounders between the PAD
and no PAD cohorts but is unable to account for unmeasured
confounders. In addition, this study included a relatively small
sample of patients with PAD compared with those without
PAD because only 4.9% of patients included in this study had
PAD. The power to detect similarities and differences in
patient characteristics and baseline demographics is limited.
Moreover, the results of our ﬁndings may not be generalizable
to other non–clinical trial populations. In addition, patients
with PAD in our study were identiﬁed as determined by site
investigators. The severity of PAD in our subgroup is not
known. Finally, although cerebrovascular disease was distin-
guished from PAD on the case report form, the disease
burden and symptom status (eg, asymptomatic PAD, inter-
mittent claudication, or critical limb ischemia) of PAD patients
were not measured or recorded by site investigators. Because
these factors inﬂuence morbidity and mortality with PAD, they
could lead to imprecise ﬁndings in this small group of patients
with PAD in ARISTOTLE.
Conclusions
Patients with AF and PAD had higher rates of death and
trends toward higher rates of stroke or systemic embolism
and bleeding than patients without PAD. The beneﬁts of
apixaban compared with warfarin for stroke and death were
similar in patients with and without PAD. In the relatively small
subgroup of patients with PAD in ARISTOTLE, no statistically
signiﬁcant reduction in major or clinically relevant nonmajor
bleeding was observed in the larger population of patients
without PAD. These ﬁndings highlight the need to optimize the
treatment of patients with AF and PAD.
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Table S1. Proportional hazards regression models for PAD-by-treatment interactions on ISTH bleeding endpoints 
 
Variable 
No PAD, 
apixaban 
No PAD, 
warfarin 
No PAD 
unadjusted HR 
(95% CI) 
No PAD 
adjusted HR 
(95% CI) 
PAD, 
apixaban 
PAD, 
warfarin 
PAD unadjusted 
HR (95% CI) 
PAD adjusted 
HR (95% CI) 
Unadjusted 
interaction 
p-value 
Adjusted 
interaction 
p-value 
Clinically relevant non-major 
bleeding 
1.99 
(287) 
3.03 
(423) 
0.66 (0.57, 
0.77) 
0.65 (0.56, 
0.75) 
3.77 (26) 2.82 
(19) 
1.36 (0.75, 
2.46) 
1.39 (0.77, 2.50) 0.0201 0.0149 
Major bleeding 2.10 
(303) 
3.03 
(428) 
0.69 (0.60, 
0.80) 
0.68 (0.59, 
0.79) 
3.04 (21) 3.81 
(26) 
0.81 (0.45, 
1.44) 
0.81 (0.46, 1.44) 0.6176 0.5772 
Major bleeding type 
Required transfusion 0.84 
(123) 
1.20 
(171) 
0.71 (0.56, 
0.89) 
0.69 (0.54, 
0.86) 
1.87 (13) 2.04 
(14) 
0.97 (0.45, 
2.06) 
0.95 (0.45, 2.04) 0.4399 0.4125 
Required a medical or 
surgical intervention to stop 
bleeding 
0.63 (92) 0.88 
(126) 
0.72 (0.55, 
0.94) 
0.70 (0.53, 
0.92) 
0.86 (6) 0.87 (6) 0.98 (0.32, 
3.05) 
1.00 (0.32, 3.11) 0.5952 0.5495 
Required changes in 
antithrombotic therapy 
1.10 
(160) 
1.41 
(200) 
0.79 (0.64, 
0.97) 
0.77 (0.63, 
0.95) 
2.16 (15) 2.64 
(18) 
0.84 (0.42, 
1.66) 
0.83 (0.42, 1.66) 0.8614 0.8282 
Required hospitalization 1.02 
(149) 
1.33 
(189) 
0.77 (0.62, 
0.96) 
0.76 (0.61, 
0.94) 
1.72 (12) 2.48 
(17) 
0.72 (0.34, 
1.50) 
0.72 (0.34, 1.50) 0.8472 0.8921 
Major bleeding site 
Intracranial 0.34 (50) 0.80 
(115) 
0.43 (0.31, 
0.60) 
0.42 (0.30, 
0.59) 
0.28 (2) 1.02 (7) 0.26 (0.05, 
1.25) 
0.26 (0.05, 1.24) 0.5353 0.5444 
 
PAD=peripheral artery disease 
HR=hazard ratio 
CI=confidence interval 
ISTH=International Society on Thrombosis and Haemostasis 
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